ReviewCurrent rheumatology reports2014
Amyopathic dermatomyositis: definitions, diagnosis, and management.
Review in Current rheumatology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06857240 (Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Who cites it
44 citing papers in PubMed, 86 citations in OpenAlex.
- The Spectrum of Cutaneous Manifestations in Dermatomyositis: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Development of siRNAs targeting interferon beta as a novel therapeutic approach for adult and juvenile dermatomyositis.Frontiers in immunology · 2026Article
- AQP4+ NMOSD, MDA5+ Clinically Amyopathic Dermatomyositis and sHLH in a Pediatric Patient: A Case Report and Literature Review.Journal of inflammation research · 2026Article
- Multisystemic Complications and Rapid Decline in Anti-MDA-5 Positive Amyopathic Dermatomyositis: A Case Study.Clinical case reports · 2025Article
- Clinical characteristics and prognosis of amyopathic dermatomyositis patients with interstitial lung disease: insights from a retrospective cohort.Orphanet journal of rare diseases · 2025Article
- Recognition of Idiopathic Inflammatory Myopathies Underlying Interstitial Lung Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Exhaustion of NK cells and interferon activation in anti-MDA5Frontiers in immunology · 2025Article
- Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database.Journal of the American Academy of Dermatology · 2024Article
- Anti-TIF-1γ dermatomyositis: Erythematous eruption with weakness and normal creatine kinase.Skin health and disease · 2024Article
- Prognostic analysis of MDA5-associated clinically amyopathic dermatomyositis with interstitial lung disease.Immunity, inflammation and disease · 2024Article
- A 30-year-old female with dermatomyositis without high elevation of muscle enzymes: a rare case report from Syria.Annals of medicine and surgery (2012) · 2024Article
- Clinically amyopathic dermatomyositis associated with cutaneous ulcerations: a case-based review.Annals of medicine and surgery (2012) · 2024Article
- Dermatomyositis: Practical Guidance and Unmet Needs.ImmunoTargets and therapy · 2024Review
- Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case-Control Study.Rheumatology and therapy · 2023Article
- Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist.The Journal of rheumatology · 2023Review
- Management of dermatomyositis patients amidst the COVID-19 pandemic: Two case reports.Medicine · 2022Article
- Clinical characteristics of idiopathic interstitial pneumonias with anti-Ro52/tripartite motif-containing 21 antibodies.Scientific reports · 2022Article
- Myositis-specific Antibodies: Overview and Clinical Utilization.Rheumatology and immunology research · 2022Review
- Review
- Acute interstitial pneumonia due to amyopathic dermatomyositis.Proceedings (Baylor University. Medical Center) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Amyopathic dermatomyositis can be a challenging diagnosis because patients lack traditional muscle findings. "Clinically amyopathic" dermatomyositis (CADM) accounts for the presence of subclinical muscle disease in some of these patients. These patients represent a substantial minority of dermatomyositis cases and have similar co-morbidities to "classic" dermatomyositis patients, including interstitial lung disease and malignancy. Clinically amyopathic dermatomyositis patients should not be considered as a distinct clinical entity from "classic" dermatomyositis, as they share antibody sub-types and associated co-morbidities, likely representing clinical spectrum of a common disease. It is essential for the clinician to be familiar with the clinical presentation of clinically amyopathic dermatomyositis, in order to facilitate early, accurate diagnosis and appropriate clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.